DURECT CORPORATION (DRRX) Stock Fundamental Analysis
USA - NASDAQ:DRRX - US2666055007 - Common Stock
1.91 USD
-0.02 (-1.04%)
1.94 USD
+0.03 (+1.57%)
DRRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While DRRX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, DRRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year DRRX has reported negative net income.
In the past year DRRX has reported a negative cash flow from operations.
DRRX had negative earnings in each of the past 5 years.
DRRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
DRRX has a Return On Assets of -27.86%. This is comparable to the rest of the industry: DRRX outperforms 54.31% of its industry peers.
DRRX has a Return On Equity (-99.86%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| ROIC | N/A |
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DRRX's Gross Margin of 62.60% is fine compared to the rest of the industry. DRRX outperforms 70.56% of its industry peers.
In the last couple of years the Gross Margin of DRRX has remained more or less at the same level.
DRRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
2. Health
2.1 Basic Checks
DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
DRRX has more shares outstanding than it did 1 year ago.
DRRX has more shares outstanding than it did 5 years ago.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DRRX has an Altman-Z score of -67.96. This is a bad value and indicates that DRRX is not financially healthy and even has some risk of bankruptcy.
DRRX has a Altman-Z score of -67.96. This is amonst the worse of the industry: DRRX underperforms 92.39% of its industry peers.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -67.96 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
DRRX has a Current Ratio of 0.98. This is a bad value and indicates that DRRX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of DRRX (0.98) is worse than 80.71% of its industry peers.
A Quick Ratio of 0.95 indicates that DRRX may have some problems paying its short term obligations.
DRRX has a worse Quick ratio (0.95) than 74.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
DRRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.61%, which is quite impressive.
DRRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.89%.
DRRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -39.51% yearly.
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%
3.2 Future
DRRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 60.95% yearly.
The Revenue is expected to grow by 53.91% on average over the next years. This is a very strong growth
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DRRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DRRX's earnings are expected to grow with 57.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
5. Dividend
5.1 Amount
DRRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.91
-0.02 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners22.34%
Inst Owner Change-0.99%
Ins Owners11.82%
Ins Owner Change-0.75%
Market Cap59.31M
Revenue(TTM)3.12M
Net Income(TTM)-3478000
Analysts45.71
Price Target2.55 (33.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.78%
Min EPS beat(2)-9.24%
Max EPS beat(2)42.81%
EPS beat(4)3
Avg EPS beat(4)391.47%
Min EPS beat(4)-9.24%
Max EPS beat(4)1511.48%
EPS beat(8)6
Avg EPS beat(8)215.39%
EPS beat(12)10
Avg EPS beat(12)147.91%
EPS beat(16)13
Avg EPS beat(16)114.43%
Revenue beat(2)2
Avg Revenue beat(2)24.63%
Min Revenue beat(2)7.9%
Max Revenue beat(2)41.37%
Revenue beat(4)2
Avg Revenue beat(4)-9.47%
Min Revenue beat(4)-82.8%
Max Revenue beat(4)41.37%
Revenue beat(8)3
Avg Revenue beat(8)-13.96%
Revenue beat(12)3
Avg Revenue beat(12)-15.73%
Revenue beat(16)5
Avg Revenue beat(16)-0.21%
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 19.01 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 17.03 | ||
| P/tB | 78.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.1
BVpS0.11
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.6% | ||
| FCFM | N/A |
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
F-Score3
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.65% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | -67.96 |
F-Score3
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)86.47%
Cap/Depr(5y)78.99%
Cap/Sales(3y)0.86%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
EBIT growth 1Y32.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.28%
OCF growth 3YN/A
OCF growth 5YN/A
DURECT CORPORATION / DRRX FAQ
Can you provide the ChartMill fundamental rating for DURECT CORPORATION?
ChartMill assigns a fundamental rating of 2 / 10 to DRRX.
What is the valuation status of DURECT CORPORATION (DRRX) stock?
ChartMill assigns a valuation rating of 1 / 10 to DURECT CORPORATION (DRRX). This can be considered as Overvalued.
How profitable is DURECT CORPORATION (DRRX) stock?
DURECT CORPORATION (DRRX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for DRRX stock?
The Earnings per Share (EPS) of DURECT CORPORATION (DRRX) is expected to decline by -105.89% in the next year.